Literature DB >> 15509157

A cyclopent-2-enecarbonyl group mimics proline at the P2 position of prolyl oligopeptidase inhibitors.

Elina M Jarho1, Jarkko I Venäläinen, Juhani Huuskonen, Johannes A M Christiaans, J Arturo Garcia-Horsman, Markus M Forsberg, Tomi Järvinen, Jukka Gynther, Pekka T Männistö, Erik A A Wallén.   

Abstract

With the aim to replace the natural amino acid proline by a proline mimetic structure, a cyclopent-2-enecarbonyl moiety was studied at the P2 position of prolyl oligopeptidase (POP) inhibitors. The cyclopent-2-enecarbonyl moiety proved to be an excellent proline mimetic at the P2 position of POP inhibitors. The replacement is particularly useful when increased lipophilicity is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15509157     DOI: 10.1021/jm049503w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  13 in total

1.  Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways.

Authors:  I Peltonen; T T Myöhänen; P T Männistö
Journal:  Neurochem Res       Date:  2012-06-23       Impact factor: 3.996

2.  Tetrazole as a Replacement of the Electrophilic Group in Characteristic Prolyl Oligopeptidase Inhibitors.

Authors:  Tommi P Kilpeläinen; Jonna K Tyni; Maija K Lahtela-Kakkonen; Tony S Eteläinen; Timo T Myöhänen; Erik A A Wallén
Journal:  ACS Med Chem Lett       Date:  2019-11-11       Impact factor: 4.345

3.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

5.  A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.

Authors:  T T Myöhänen; M J Hannula; R Van Elzen; M Gerard; P Van Der Veken; J A García-Horsman; V Baekelandt; P T Männistö; A M Lambeir
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

6.  Targeting NOX2 via p47/phox-p22/phox Inhibition with Novel Triproline Mimetics.

Authors:  Jean-Baptiste Garsi; Balázs Komjáti; Gregorio Cullia; Imre Fejes; Melinda Sipos; Zoltán Sipos; Eszter Fördős; Piroska Markacz; Barbara Balázs; Nathalie Lancelot; Sylvie Berger; Eric Raimbaud; David Brown; Laurent-Michel Vuillard; Laure Haberkorn; Cyprian Cukier; Zoltán Szlávik; Stephen Hanessian
Journal:  ACS Med Chem Lett       Date:  2022-05-10       Impact factor: 4.632

7.  Prolyl Oligopeptidase Regulates Dopamine Transporter Phosphorylation in the Nigrostriatal Pathway of Mouse.

Authors:  Ulrika H Julku; Anne E Panhelainen; Saija E Tiilikainen; Reinis Svarcbahs; Anne E Tammimäki; T Petteri Piepponen; Mari H Savolainen; Timo T Myöhänen
Journal:  Mol Neurobiol       Date:  2016-12-13       Impact factor: 5.590

8.  The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.

Authors:  Mari H Savolainen; Christopher T Richie; Brandon K Harvey; Pekka T Männistö; Kathleen A Maguire-Zeiss; Timo T Myöhänen
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

9.  Spatiotemporal expression and inhibition of prolyl oligopeptidase contradict its involvement in key pathologic mechanisms of kainic acid-induced temporal lobe epilepsy in rats.

Authors:  Idrish Ali; Annemie Van Eetveldt; Roos Van Elzen; Tom Kalathil Raju; Pieter Van Der Veken; Anne-Marie Lambeir; Stefanie Dedeurwaerdere
Journal:  Epilepsia Open       Date:  2018-12-24

10.  Selective Homogeneous Assay for Circulating Endopeptidase Fibroblast Activation Protein (FAP).

Authors:  Travis W Bainbridge; Diana Ronai Dunshee; Noelyn M Kljavin; Nicholas J Skelton; Junichiro Sonoda; James A Ernst
Journal:  Sci Rep       Date:  2017-10-02       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.